Categories: PR Newswire

New Research Shows High-Concentration Ashwagandha Root Extract can be an Effective Sleep and Anxiety Aid

LOS ANGELES, Oct. 9, 2019 /PRNewswire/ — A new double-blind, randomized, placebo-controlled human clinical study published on September 28 in Cureus shows KSM-66 Ashwagandha can be a safe, effective solution to insomnia and the anxiety that often accompanies it. KSM-66 was shown to improve both quantity and quality of sleep.

Sixty subjects with insomnia were randomized in a 2:1 ratio to receive KSM-66 Ashwagandha root extract capsules in a 300 mg dose twice daily or an identical placebo, for a period of 10 weeks. Monitoring rest and activity patterns through a combination of sleep logs, self-reporting and actigraphy (a standard, non-invasive tool for studying sleep patterns), researchers found statistically significant improvements in sleep quality along the following important metrics: sleep onset latency, total sleep time, wake after sleep onset, total time in bed, sleep efficiency, the Pittsburgh sleep quality index, subjective sleep quality assessment and mental alertness on rising. Those who consumed KSM-66 Ashwagandha also experienced a significant reduction is stress. This is consistent with several previous studies that showed KSM-66 to significantly reduce the concentration of the stress hormone cortisol in the blood, promoting a greater feeling of ease.

“The new study corroborates the use of Ashwagandha root extract as a first-class adaptogen that helps promote restful sleep and reduce anxiety,” says ethnobotanist, Medicine Hunter Christopher Kilham, who served for 14 years as Explorer in Residence at the University of Massachusetts, Amherst. “We know that Americans are not getting enough sleep. Ashwagandha offers a simple, safe and natural way to achieve deep sleep for badly needed rest and repair, without drowsiness or negative effects. You simply do not need to resort to potentially harmful or addictive drugs to achieve healthy sleep.” Ixoreal CEO Kartikeya Baldwa added: “Sleep is of course critical to well-being and healthy functioning. Published research has associated insomnia with chronic diseases such as obesity, type 2 diabetes, cardiovascular disease, neurological issues, mood swings, and increased mortality.”

KSM-66 Ashwagandha is made by Ixoreal Biomed of Hyderabad, India, and Los Angeles, California. It is the most clinically studied ashwagandha extract, the subject of 22 human clinical trials. It is used in over 700 products in 45 countries including brands like Youtheory, Nature’s Bounty, Puritan’s Pride, Jarrow, GNC, CVS, REBBL Beverages and Natures Sunshine.

For more information, visit https://ksm66ashwagandhaa.com.

Contact:
Dean Draznin
641-472-2257
dean@drazninpr.com

SOURCE KSM-66 Ashwagandha

Related Links

https://ksm66ashwagandhaa.com

IR Press

Share
Published by
IR Press

Recent Posts

Treasury Sanctions Entities in Iran and Russia That Attempted to Interfere in the U.S. 2024 Election

WASHINGTON – Today, the Department of the Treasury’s Office of Foreign Assets Control (OFAC) is…

1 day ago

Treasury Sanctions Russian Judge for Arbitrary Detention of Alexei Gorinov

WASHINGTON – Today, the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC)…

1 day ago

U.S. Department of the Treasury Releases Final Regulations Implementing Bipartisan Tax Reporting Requirements for Brokers of Digital Assets

Regulations help make filing easier for digital asset holders on taxes already owed WASHINGTON – As part of…

5 days ago

OCC Issues Annual Report for 2024

WASHINGTON—The Office of the Comptroller of the Currency (OCC) today published its 2024 Annual Report.…

2 weeks ago

OCC Announces Enforcement Actions for December 2024

WASHINGTON—The Office of the Comptroller of the Currency (OCC) today released enforcement actions taken against…

2 weeks ago

Treasury Maintains Pressure on Houthi Procurement and Financing Schemes

WASHINGTON — Today, the Department of the Treasury’s Office of Foreign Assets Control (OFAC) sanctioned…

2 weeks ago